147 filings
Page 2 of 8
NT 10-Q
7u3i6cr62c34c
14 Nov 22
Notice of late quarterly filing
4:53pm
8-K
yrevccm1iocmnkshcnvg
19 Aug 22
Departure of Directors or Certain Officers
1:20pm
NT 10-Q
lf8wid5vc5q5f 0ni
16 Aug 22
Notice of late quarterly filing
2:48pm
8-K
cqwj00cwsb34vdla bm
28 Jul 22
CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million
9:51am
NT 10-K
qw6 kw42y
31 Mar 22
Notice of late annual filing
7:52pm
8-K
pani77rwv37p0qjee7mq
7 Jan 22
Entry into a Material Definitive Agreement
4:30pm
8-K
l5p7ao2t5nfsl lglorr
3 Dec 21
Departure of Directors or Certain Officers
4:01pm
8-K
ve9pevtz0dltx92q
29 Apr 21
Entry into a Material Definitive Agreement
9:15am
8-K
5zofxfew
6 Apr 21
CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020
4:30pm
8-K
raw4txry5cjfdfie
25 Feb 21
Entry into a Material Definitive Agreement
4:30pm
8-K
sc1liihr
12 Feb 21
CURE Pharmaceutical Announces Promotions and Additions to Board of Directors
5:29pm
8-K
vc268a
6 Jan 21
CURE Pharmaceutical Receives FDA Approval for its IND Application
9:15am